19 / 24
Page 45
Current Research: Integrative Medicine
CAM Therapies 2017
September 18-19, 2017 Charlotte, USA
5
th
International Meeting on
Complementary and Alternative Medicine & Therapies
Ginkgo biloba L
extract enhances the anti-tumor effects of PDTC
Fanzhu Meng, Shuhan Xiong
and
Shuping Ren
Jilin University School of Public Health, China
T
o explore whether combination of
Ginkgo biloba L
extract (EGB) and pyrrolidine dithiocarbamate (PDTC)
will produce a better inhibition on the growth of H22 cells in the experiment animals. H22 was injected at the
right thigh of the mice at the concentration of 1X106 cells/ mouse followed by random distribution of these mice
into 4 groups, PBS, PDTC, EGB, EGB+PDTC. 24 h later, the mice were administered PBS, or PDTC, or EGB, or
EGB+PDTC based on their group. The administration was conducted consecutively for 26 days when all the mice
in PBS group developed palpated tumor. The tumor weight and volume, the levels of MDA and ROS in serum,
the activities of SOD and GSH-Px in serum and the expression of NF-κB65 were compared among different
groups. Compared with the mice treated with EGB, or PDTC, the mice treated with both EGB and PDTC showed
significantly smaller tumor weight and volume, significantly longer of latency of tumor growth; significantly
higher activities of SOD and GSH-Px, significantly lower level of MDA and ROS, significantly lower level
expression of NF-κB. Combination of
Ginkgo biloba L
extract (EGB) and pyrrolidine dithiocarbamate (PDTC)
can produce a better inhibition on the growth of H22 cells in the experiment animals.
503427305@qq.com